FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

被引：0
作者：
Peter A Fasching
Sebastian M Jud
Maik Hauschild
Sherko Kümmel
Martin Schütte
Matthias Warm
Volker Hanf
Dieter Grab
Jutta Krocker
Elmar Stickeler
Rolf Kreienberg
Thomas Müller
Thorsten Kühn
Christopher Wolf
Steffen Kahlert
Stefan Paepke
Michael Berghorn
Mathias Muth
Monika Baier
Birgit Wackwitz
Rüdiger Schulz-Wendtland
Matthias W Beckmann
Michael P Lux
机构：
[1] Erlangen Comprehensive Cancer Center Erlangen-EMN,University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich Alexander University of Erlangen–Nuremberg
[2] Departement of Gynecology and Obstetrics,Department of Gynecology and Obstetrics
[3] Breast Center,Department of Gynecology and Obstetrics
[4] Klinikum Essen-Mitte,Department of Gynecology and Obstetrics
[5] Essen University Hospital,Department of Gynecology and Obstetrics
[6] Cologne University Hospital,Department of Gynecology and Obstetrics
[7] Kliniken der Stadt Köln Holweide,Department of Gynecology and Obstetrics
[8] Clinic for Gynecology and Obstetrics "Nathanstift" Klinikum Fürth,Department of Gynecology and Obstetrics
[9] Klinikum Harlaching,Frauenklinik Grosshadern
[10] Sana-Klinikum Lichtenberg,Institute of Diagnostic Radiology, Erlangen University Hospital
[11] Oskar-Ziethen-Krankenhaus,undefined
[12] Freiburg University Hospital,undefined
[13] Ulm University Hospital,undefined
[14] Frauenklinik,undefined
[15] Klinikum Hanau,undefined
[16] Klinikum Esslingen,undefined
[17] Medizinisches Zentrum Ulm,undefined
[18] Frauenklinik und Poliklinik der Technischen Universität München,undefined
[19] Universitätsklinik der Ludwig-Maximilians-Universität,undefined
[20] Frauenklinik,undefined
[21] Allgemeines Krankenhaus Celle,undefined
[22] Novartis Pharma GmbH,undefined
[23] Friedrich Alexander University of Erlangen–Nuremberg,undefined
来源：
BMC Cancer | / 14卷
关键词：
Zoledronic acid; Neoadjuvant treatment; Breast cancer; Letrozole; Aromatase inhibitors; Bisphosphonates;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 226 条
[1]  
Kolberg HC(2012)Breast Cancer 2012-New Aspects Geburtsh Frauenheilk 72 602-615
[2]  
Luftner D(2006)Breast cancer: bisphosphonate therapy for metastatic bone disease Clin Canc Res Off J Am Assoc Canc Res 12 6258s-6263s
[3]  
Lux MP(2008)Bisphosphonate treatment and radiotherapy in metastatic breast cancer Med Oncol 25 350-355
[4]  
Maass N(2011)Breast-cancer adjuvant therapy with zoledronic acid New Engl J Med 365 1396-1405
[5]  
Schutz F(2009)Endocrine therapy plus zoledronic acid in premenopausal breast cancer New Engl J Med 360 679-691
[6]  
Fasching PA(2010)Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study Ann Oncol Off J Euro Soc Med Oncol ESMO 21 2188-2194
[7]  
Fehm T(2011)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 631-641
[8]  
Janni W(2002)Pamidronate induces modifications of circulating angiogenetic factors in cancer patients Clin Canc Res Off J Am Assoc Can Res 8 1080-1084
[9]  
Kummel S(2003)Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Canc Res Off J Am Assoc Canc Res 9 2893-2897
[10]  
Body JJ(2007)Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Canc Res Off J Am Ass Canc Res 13 4482-4486
12345678910